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Serological and molecular 
epidemiology of canine adenovirus 
type 1 in red foxes (Vulpes vulpes) in 
the United Kingdom
David Walker1, Seán A. Fee2, Gill Hartley3, Jane Learmount4, Maria J. H. O’Hagan5, 
Anna L. Meredith1, Barend M. de C. Bronsvoort1, Thibaud Porphyre1, Colin P. Sharp1 & 
Adrian W. Philbey1
Canine adenovirus type 1 (CAV-1) causes infectious canine hepatitis (ICH), a frequently fatal disease 
which primarily affects canids. In this study, serology (ELISA) and molecular techniques (PCR/qPCR) 
were utilised to investigate the exposure of free-ranging red foxes (Vulpes vulpes) to CAV-1 in the United 
Kingdom (UK) and to examine their role as a wildlife reservoir of infection for susceptible species. The 
role of canine adenovirus type 2 (CAV-2), primarily a respiratory pathogen, was also explored. In foxes 
with no evidence of ICH on post-mortem examination, 29 of 154 (18.8%) red foxes had inapparent 
infections with CAV-1, as detected by a nested PCR, in a range of samples, including liver, kidney, 
spleen, brain, and lung. CAV-1 was detected in the urine of three red foxes with inapparent infections. 
It was estimated that 302 of 469 (64.4%) red foxes were seropositive for canine adenovirus (CAV) by 
ELISA. CAV-2 was not detected by PCR in any red foxes examined. Additional sequence data were 
obtained from CAV-1 positive samples, revealing regional variations in CAV-1 sequences. It is concluded 
that CAV-1 is endemic in free-ranging red foxes in the UK and that many foxes have inapparent 
infections in a range of tissues.
Infectious canine hepatitis (ICH) is caused by canine adenovirus type 1 (CAV-1) and can cause severe and fatal 
disease, primarily in domestic dogs and other canids1. The disease first came to prominence in the early 20th cen-
tury, having been described as “epizootic fox encephalitis” in farmed silver foxes, a colour variant of the red fox 
(Vulpes vulpes), in North America2. Clinical signs of ICH in dogs and foxes include sudden death, neurological 
signs and jaundice. Lesions in dogs and foxes include severe necrotising hepatitis, disseminated intravascular 
coagulation (DIC) and vasculitis, the latter manifesting as encephalitis and glomerulonephritis, caused by viral 
replication in hepatocytes and vascular endothelial cells3,4. Mortality from experimental infections is 10–25% in 
red foxes and 10–30% in dogs5.
Most documented information relating to the clinical course of non-experimental ICH is based on reports 
of natural disease in domestic dogs. However, there have been several documented cases of ICH in free-ranging 
species, including a grey fox (Urocyon cinereoargenteus) in Georgia, USA6, and three cases in red foxes in the UK7. 
Furthermore, disease appears not to be restricted to canids; fatal ICH has been suspected in hospitalised black 
bear cubs (Ursus americanus) in the USA8 and a captive Eurasian otter (Lutra lutra) in Seoul, South Korea9.
CAV-1 is widely distributed geographically and evidence of infection has been found amongst canid species 
worldwide7,10. The prevalence of antibodies against untyped canine adenovirus (CAV) can be particularly high in 
free-ranging canid species; for example, 188 of 194 (97%) island foxes (Urocyon littoralis) in the Californian Channel 
Islands11 and 54 of 57 (94.7%) of wolves (Canis lupus) in Alaska12 had antibodies against CAV. In Europe, neutralising 
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antibodies against CAV were detected in sera from 17 of 485 (3.5%) red foxes in Germany10 and in tissue fluid extracts 
from 11 of 58 (19%) red foxes in England and Scotland7. However, this seropositivity is not necessarily specific for 
CAV-1, since there is substantial cross-reactivity between CAV-1 and canine adenovirus type 2 (CAV-2); CAV-2 
which is implicated in infectious tracheobronchitis in dogs1. Cross-protection between the two viruses is 
exploited by the routine use of CAV-2-based vaccines in veterinary practice to protect dogs against ICH. There is 
no current evidence to suggest that CAV-2 is pathogenic in foxes, although Balboni et al.13 reported detection of 
CAV-2 by the polymerase chain reaction (PCR) in the faeces of a free-ranging red fox in Italy.
The population of red foxes in the UK is estimated to be approximately 258,000 and this species, the only wild 
canid in the UK, has adapted well to urban environments14. Domestic dogs are therefore likely to come into indi-
rect (or rarely direct) contact with foxes via urine, faeces and infected fomites. In active infections, CAV-1 is shed 
in urine, faeces and possibly other secretions1; therefore, concern has been raised that red foxes may be a wildlife 
reservoir of CAV-17,13, as well as other pathogens, such as Angiostrongylus vasorum15. In a study of outbreaks of 
ICH amongst captive juvenile red foxes in wildlife hospitals in the UK, an apparently healthy fox, thought to be 
shedding infectious CAV-1, was the likely cause of one outbreak4. To determine whether foxes are a significant 
reservoir of CAV-1, and thus a source of infection for dogs and other susceptible species, it is important to deter-
mine the prevalence of infection (including inapparent infection) with CAV-1 amongst seemingly healthy foxes 
in the UK and other countries with high densities of foxes.
To date, the impact and prevalence of CAV-1 in wildlife in the UK has not been fully assessed. This is due, in 
part, to the practical difficulty in obtaining large sample sizes, an inherent limitation in many wildlife surveys. 
Furthermore, there is some evidence suggesting that CAV-1 establishes persistent infections in renal tubular 
epithelial cells in a proportion of domestic dogs and that virus is shed in the urine of these animals for up to 9 
months16. Therefore, CAV-1 may persist and/or be excreted for varying periods of time at low levels during inap-
parent infections and it is desirable that more sensitive molecular techniques, such as nested PCR or quantitative 
real-time PCR (qPCR), are developed for detecting potentially low copy number CAV-1 DNA, so as to minimise 
false negative results in molecular surveys.
The aim of this study was to examine the role of red foxes in the UK as a wildlife reservoir of CAV-1 and as a 
potential source of infection for domestic dogs. In this survey, the first in the UK to use molecular methods for the 
detection and sequencing of CAV-1, we investigated the epidemiology of CAV-1 in red foxes across the UK, com-
prising Great Britain (GB, which includes England, Scotland and Wales) and Northern Ireland (NI); the occur-
rence of CAV-1 in red foxes in Wales and NI has not been assessed previously. The survey combined serology, 
using an indirect enzyme-linked immunosorbent assay (ELISA), and molecular investigations, using a nested 
PCR. A probe-based qPCR was also developed to estimate viral loads in CAV-1 infected samples, including tis-
sues and urine. Viral loads were quantified for the first time in urine, which is considered to be one of the primary 
routes of CAV-1 transmission in active infections1. We also examined whether red foxes might harbour CAV-2.
Materials and Methods
Specimen collection and processing. The project was approved by the Royal (Dick) School of Veterinary 
Studies (RDSVS), University of Edinburgh, Veterinary Ethical Review Committee (VERC; approval number 103 14). 
Methods were performed in accordance with relevant guidelines and regulations. All samples in the study were 
obtained as excess clinical material or as by-products of other activities and events, unrelated to the study. Tissues 
were obtained from red fox carcasses originating from a variety of sources throughout the UK. A number of 
animals were collected as a result of land and game management regimes in the Lothians and Borders, Scotland, 
and in Cumbria, England. Carcasses obtained in this manner were refrigerated at 4 °C or frozen at − 20 °C before 
undergoing post-mortem examination. Foxes were also collected opportunistically from incidents of road traffic 
accidents (RTAs) or from natural causes of death in Edinburgh and the Lothians and Borders, Scotland. Tissues 
which had been stored at − 80 °C were also utilised from a prior study by Meredith et al.17.
Other foxes were obtained from wildlife hospitals in Scotland and England, where foxes had died as a result of 
injury or disease, not including clinical cases of ICH, or had been euthanased by a lethal injection of barbiturate 
on humane grounds. Carcasses were stored at − 20 °C prior to collection for examination. Blood samples included 
in the study were also obtained from Tiggywinkles Wildlife Hospital, Haddenham, England. Animals which had 
been euthanased due to disease or injury unrelated to ICH at the RDSVS, were also included in the study. Clinical 
records were interrogated following each post-mortem examination when possible.
The Animal and Plant Health Agency (APHA), England, Science and Advice for Scottish Agriculture (SASA), 
Scotland, and the Agri-Food and Biosciences Institute (AFBI), NI, routinely perform post-mortem examinations 
on fox carcasses for disease surveillance (foxes submitted to AFBI were initially collected by the Department 
of Agriculture, Environment and Rural Affairs, NI; DAERA)18,19. Carcasses are provided to these organisations 
mainly as a result of land and estate management, or sometimes as RTAs or natural causes of death. Blood sam-
ples from foxes from these large-scale surveys were subsequently made available for testing, including samples 
previously utilised by Taylor et al.15 in an unrelated study. AFBI and SASA provided tissue samples from NI and 
Scotland, respectively.
When possible, relevant individual data, such as sex, weight and body condition score (BCS), were recorded 
during post-mortem examination. The age of each fox undergoing post-mortem examination at the RDSVS was 
estimated on the basis of size, body weight and dentition. To allow data to be merged with that recorded by AFBI 
and Taylor et al.15, foxes were assigned to an estimated age class (1 = cub/juvenile, 2 = young adult, 3 = aged 
adult). Similarly, BCS was scored subjectively (1 = poor, 2 = fair, 3 = good), based on a range of factors, includ-
ing external and internal fat coverage and muscle mass. Any significant gross lesions were also recorded during 
the post-mortem examination. The location from where carcasses were collected (grid references, geographical 
coordinates or place names) were available for most samples. However, the origin of most red foxes admitted to 
wildlife hospitals could not be traced accurately. Locations, where available, were converted and standardised 
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to longitudes and latitudes to account for the multiple measurement formats. Foxes were also assigned to larger 
regions, designated NI, Scotland, North England, Midlands and Wales (Central), South East England or South 
West England.
A range of tissues and samples were collected from foxes in Scotland. The tissues collected, when full sets 
could be obtained, were blood, liver, kidney, spleen, small intestine, brain, lung, urine and faeces. When the full 
array of tissues could not be collected, for example due to carcass damage or scavenging, a subset was collected. 
Only blood, liver and kidney samples were collected from foxes from NI. Samples were collected into polypropyl-
ene containers and stored at − 20 °C prior to further processing. After collection, blood samples were centrifuged 
to remove debris and stored at − 20 °C. DNA from tissues and urine samples was extracted using the DNA Blood 
and Tissue Kit (Qiagen, Hilden, Germany), whilst DNA from faecal samples was extracted using the E.Z.N.A 
Stool DNA Kit (Omega Bio-tek, Norcross, Georgia, USA), then stored at − 20 °C prior to further testing.
A total of 154 foxes from across the UK were included in the molecular survey and a total of 469 foxes were 
included in the serological survey.
CAV-1/CAV-2 specific PCR protocol. Liver and kidney were classified as the ‘sentinel’ organs for CAV-1 
infection in this study; liver is one of the main organs infected during the acute stages of ICH in dogs1, and the 
kidney is considered to be a sentinel organ for ‘chronic’ infection (although it is also infected early in infection) 
when animals may be shedding virus in their urine20. Therefore, only foxes where both liver and kidney were 
collected were included in the study; DNA extracted from these organs was screened for CAV-1 in all foxes. PCR 
was performed to screen for both CAV-1 and CAV-2 in the urine and faeces of animals from which these samples 
were collected, to detect animals which were shedding virus. When a positive result was obtained in DNA extracts 
from liver and/or kidney, DNA extracts from all other samples collected during the post-mortem examination of 
the positive animals were tested.
We hypothesised that a low copy number of CAV-1 DNA, particularly in animals without clinical signs or 
gross lesions typical of ICH, would be present in infected tissues. Therefore, we developed a nested PCR proto-
col specific for CAV-1 using the CAV-1 reference sequence (EMBL AC_000003.1) (Table 1). An alternative set 
of nested primers was also developed to detect CAV-2 (EMBL AC_000020.1) (Table 1). The primer sets were 
designed against a region of the genome to allow discrimination between CAV-1 and CAV-2, which corresponded 
to putative ORF7 (GenBank Y07760.1).
The PCR first-round reaction mixture for CAV-1 consisted of 35.8 μ L H2O, 0.2 μ L (1 U) GoTaq G2 DNA 
polymerase (Promega, Madison, Wisconsin, USA), 10 μ L 5x Green GoTaq reaction buffer (Promega), 1 μ L deox-
ynucleotide triphosphates (dNTPs; final concentration 200 μ M each dNTP), 1 μ L CAV_F forward primer (final 
concentration 200 nM), 1 μ L CAV-1_R reverse primer (final concentration 200 nM) and 1 μ L DNA. Product (1 μ L) 
from the first round PCR was used as a template for the second round using the second round primer set CAV-
1_2F and CAV-1_2R. The CAV-2 reaction was identical except that the first round used the primers CAV_F and 
CAV-2_R, whilst the second round used CAV-2_2F and CAV-2_2R (Table 1). The reaction conditions were 94 °C 
for 18 s, 50 °C for 21 s and 72 °C for 1 min, repeated for 40 cycles, followed by one cycle of 72 °C for 5 min.
The specificity of the PCRs using primers designed for each CAV type was verified using clinical case mate-
rial from fatal ICH cases in foxes4 and a commercial vaccine containing CAV-2 (Nobivac DHPPi, MSD Animal 
Health, Walton, UK). PCR products from these control samples, as well as selected positive study samples, were 
also sequenced to confirm specificity (Edinburgh Genomics, Edinburgh, UK). The sensitivities of the PCRs for 
detecting CAV-1 and CAV-2 were assessed using dilutions of plasmid controls containing a CAV-1 or CAV-2 
insert (see ‘Quantitative PCR’) and was determined to be less than 10 copies.
Each DNA sample in this study was tested in triplicate, in an attempt to increase rates of detection of very low 
copy number samples and to negate possible false positive results from contamination. PCR products were loaded 
on agarose gels stained with SYBR safe DNA stain (Invitrogen, Paisley, UK) and separated by electrophoresis. 
Amplicons were observed using a G:Box gel viewing system (Syngene, Cambridge, UK). The expected amplicon 
Oligonucleotide 
name Description Nucleotide sequence (5′–3′)a,b
Nucleotide position on 
CAV-1/CAV-2 genomea,b
CAV_F CAV-1 and CAV-2, forward, 1
st 
round TAYTCATACATTTCATTGGAG
6184–6204 (CAV-1) 
6272–6292 (CAV-2)
CAV_R CAV-1 and CAV-2, reverse 1st round GCAGAAATMCCACCCGTG 6840–6857 (CAV-1)
1 
6928–6945 (CAV-2)2
CAV-1_2F CAV-1, forward, 2nd round ATTATCGTGTTTAGATGGGGGGC 6214–6236
CAV-2_2F CAV-2, forward, 2nd round AGGATGGTACTTAGGTGGTGTGT 6302–6324
CAV-1_R CAV-1, reverse, 1st round TACGTGCCTAGCAAAGATTACAGA 6735–6758
CAV-2_R CAV-2, reverse, 1st round TACGTGCCTGCCAAGAGTTACGAG 6823–6846
CAV-1_2R CAV-1, reverse, 2nd round GTAACAGCCCAGCTAGTTAACAAG 6378–6401
CAV-2_2R CAV-2, reverse, 2nd round GTAACAGCCCAGTTGGTAAACAAA 6466–6489
CAV_probe Probe, CAV-1 and CAV-2 FAM-GAGCTGATGGTTGGACGCTGGAAGAC-TAM 6289–6314 (CAV-1) 6377–6402 (CAV-2)
Table 1.  Summary of the detection primers specific for canine adenovirus type 1 (CAV-1) and type 2 
(CAV-2) and the labelled oligonucleotide probe. aEMBL AC_000003.1. bEMBL AC_000020.1.
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size of the second round product was 188 base pairs (bp) for both CAV-1 and CAV-2 primer sets. Positive ampli-
cons were confirmed by sequencing (Edinburgh Genomics).
Additional CAV-1 sequence data. An additional four sets of nested primers, based on genes or transcrip-
tional units (including hexon, fibre, E3 and E421), were designed using the reference CAV-1 genome (EMBL: 
AC_000003.1) (Table 2). The purpose of these primers was to amplify and analyse sequences in addition to those 
provided by the CAV-1 detection primer set in positive animals, allowing for comparison of different genomic 
regions amongst detected sequences from different locations in the UK. The PCR reaction mixture and ampli-
fication conditions were the same as those used for screening for CAV-1, except that 2 μ L DNA was used (and 
H2O reduced accordingly to 34.8 μ L). PCR products were confirmed to be a match for CAV-1 by direct Sanger 
sequencing (Edinburgh Genomics) using the internal primers. In the case of faint bands on agarose gels, DNA 
was extracted using the QIAquick Gel Extraction Kit (Qiagen) and cloned using the pGEM-T Easy Vector System 
(Promega) and DH5α Escherichia coli competent cells, before sequencing.
Quantitative PCR (qPCR). A CAV-1 specific probe-based qPCR protocol was developed to estimate 
the viral load of tissues positive for CAV-1 by conventional nested PCR. A dual labelled oligonucleotide probe 
was used (CAV_probe); this was labelled at the 5′ end with 6-carboxyfluorescein (FAM) and at the 3′ end with 
6-carboxytetramethylrhodamine (TAM) (Table 1). The protocol utilised the second round forward and reverse 
primers designed for the nested PCR protocol (Table 1). DNA (2 μ L) was added to a reaction mixture containing 
10 μ L Brilliant III Ultra Fast qPCR Master Mix (Agilent Technologies, Wokingham, UK), 5 μ L H2O, 1 μ L CAV_
probe dual labelled probe (final concentration 500 nM), 1 μ L CAV-1_2F forward primer and 1 μ L CAV-1_2R 
reverse primer (each final concentration 500 nM). A CAV-2 specific probe-based qPCR protocol was created 
using the same conditions and reaction mixture, substituting the CAV-1 second round primers for the CAV-2 
primers, CAV-2_2F and CAV-2_2R (Table 1).
DNA samples were repeated within each run in triplicate. Plasmids containing CAV-1 or CAV-2 DNA inserts 
were used as positive controls for the CAV-1 and CAV-2 qPCR protocols, respectively. Plasmid constructs were 
created using DH5α E. coli competent cells and the pGEM-T Easy Vector System (Promega). The insert DNA 
was the 674 bp amplicon created with a single round of PCR using the CAV_F and CAV_R primers (Table 1). The 
DNA templates for both CAV-1 and CAV-2 vectors were from field strains of virus, originating from an outbreak 
of ICH in foxes in Scotland4, and a cultured laboratory stock (University of Glasgow, Scotland, UK), respectively. 
Plasmid concentrations were estimated using a spectrophotometer (NanoDrop, Thermo Scientific, Wilmington, 
Delaware, USA). Sonified salmon sperm DNA (50 ng/μ L; AppliChem, Darmstadt, Germany) was used to dilute 
plasmids to their intended calculated dilutions. Control plasmid samples were used within each qPCR run in 
triplicate and in 10-fold dilutions ranging from 106 to 101 estimated plasmid copy numbers. ‘No template’ control 
(NTC) samples were also loaded in triplicate.
The qPCR reaction conditions followed a two-step cycle consisting of 95 °C for 10 min, then 45 cycles of 
95 °C for 15 s and 60 °C for 60 s. The qPCR cycler (Rotor-Gene, Corbett Life Science, Mortlake, Australia) was set 
to acquire FAM fluorescence signals during amplification. The resulting data were analysed using Rotor-Gene 
Q Series software (Qiagen). A threshold value for quantification was determined by automated calculation, 
requested within the software, which was manually verified and adjusted if appropriate.
Indirect enzyme-linked immunosorbent assay. An indirect ELISA was developed to assess the 
anti-CAV antibody status of red foxes in the UK by detection of immunoglobulin G (IgG) in sera or blood from 
469 red foxes. The ELISA was optimised on 96-well, flat bottomed, high binding microplates (Greiner Bio-One, 
Stonehouse, UK) using a chequer board assay following methods adapted from Crowther (2000)22. The anti-
gens were prepared as separate supernatants containing whole virus, CAV-1 (ATCC VR 293) or CAV-2 (field 
strain, University of Glasgow); the viruses were propagated in Madin-Darby canine kidney (MDCK) cell cultures. 
Virus-free supernatant was prepared for use in negative control wells. The preparations were used to coat alter-
nate wells of a microplate at a dilution of 1:80 in carbonate/bicarbonate buffer (Sigma-Aldrich, St Louis, Missouri, 
USA) in a volume of 100 μ L, at 4 °C overnight or at ambient temperature for up to 4 h.
Each well was then washed twice with 250 μ L phosphate buffered saline (PBS) containing 0.05% by volume 
Tween 20 detergent (Sigma-Aldrich) (PBS/0.05% Tween) using an automated microplate washer (Ays Atlantis, 
Biochrom, Cambridge, UK). The wells were subsequently blocked with 2% bovine serum albumin (BSA; 
Sigma-Aldrich) diluted in PBS (2% BSA/PBS) at ambient temperature for at least 2 h. Following aspiration of the 
blocking agent, each serum sample was applied at a dilution of 1:80 in a volume of 100 μ L, which was tested in 
duplicate against the three wells: (1) ‘CAV-1’, (2) ‘CAV-2’ and (3) ‘virus-free’ negative control. Each microplate 
included CAV-antibody positive and negative control fox sera, which were verified for antibody status with a virus 
neutralisation test (VNT; see below).
Wells were then aspirated and washed six times over a 1 h period. Horseradish peroxidase (HRP) conju-
gated goat anti-dog IgG (Abcam, Cambridge, UK) was diluted to 1:1600 in 100 μ L 2% BSA/PBS and applied to 
wells for 30 min. Following four washes over 30 min and aspiration of liquid, secondary antibody was detected 
using 2,2-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) substrate (Sigma-Aldrich). The optical density 
(OD) of each well was measured using a microplate reader (Multiskan Ascent, Thermo Scientific, Waltham, 
Massachusetts, USA) at a wavelength of 405 nm (OD405).
The mean OD405 reading for all samples was corrected for background reactivity by subtraction of the mean 
OD405 recorded from the virus-free control wells for each sample, and also corrected by a calculated ‘inter-plate 
variability factor’. This was calculated as the percentage difference between the OD405 of the positive control serum 
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against CAV-1 or CAV-2 on the designated reference plate (arbitrarily assigned as the first test plate) compared to 
the positive control sample on the current test plate.
An animal was declared as positive for antibodies reactive against CAV-1 or CAV-2, based on OD405 cut-off 
values calculated separately for CAV-1 and CAV-2. The cut-off values for IgG positivity were estimated using 
receiver operating characteristic (ROC) curves to provide an objective method of ELISA cut-off estimation. Data 
used for the ROC curves were OD405 values recorded from a sub-population of CAV-1 and CAV-2 antibody posi-
tive and negative control sera determined by a CAV VNT (see below). The ROC curves were computed using the 
pROC package23 within R Studio version 0.99, running R version 3.2.4 (R Studio, Boston, Massachusetts, USA)24. 
The OD405 cut-off values for CAV-1 (0.2475) and CAV-2 (0.2500) were estimated from the ROC curves using the 
‘ROC01’ method implemented by the OptimalCutpoints package25,26. A binary value was assigned to the final 
OD405 of each animal to indicate that they were positive or negative for CAV IgG (Supplementary Dataset S1).
Virus neutralisation test. A CAV VNT was developed using non-haemolysed control sera, which con-
sisted of canine sera obtained from the RDSVS and fox sera obtained from Tiggywinkles Wildlife Hospital. These 
sera were suggestive of being negative or positive for CAV IgG in the CAV ELISA (i.e. subjectively very low or 
moderate-to-high OD405) prior to the determination of the estimated absolute cut-off OD405 for the CAV ELISA 
(Supplementary Dataset S2).
The VNT was optimised following methods adapted from those described by Loeffen et al.27. Serum was 
diluted two-fold on 96-well tissue culture plates, from a dilution of 1:5 to a final dilution of 1:5120. Sera were 
tested in duplicate against both CAV-1 and CAV-2 at 100 50% tissue culture infectious doses (TCID50)/50 μ L. 
Sera were incubated with virus for 1 h at 37 °C before the addition of ~8 × 104 MDCK cells in 100 μ L cell culture 
medium. The virus load was verified by back titration of 100 TCID50 CAV-1 or CAV-2 in 10-fold dilutions ranging 
from 10−1 to 10−5. Plates were read on day 5 post-infection; wells in the plates were assigned as positive or nega-
tive for cytopathic effect (CPE). The antibody titre against CAV-1 or CAV-2 for each serum sample was calculated 
as the average titre within each duplicate. Absolute negative sera (titre = 0) were distinguished from CAV-1/
CAV-2 positive sera to identify control sera for calculation of the cut-off OD405. The cut-off was then verified by 
‘back-analysis’ of the ELISA binary result for the VNT controls.
Statistical analyses. A generalised linear model (GLM) was used to evaluate the association of the CAV 
IgG status (positive or negative) of the sampled red foxes with both demographic and environmental variables. 
The CAV IgG status used in the model was based on the estimated cut-off value applied to the mean OD405 against 
CAV-1 of sera in the ELISA. Individual descriptors included sex, age class, BCS and region of capture/collection. 
On the basis of the spatial location of the foxes, we extracted information for several habitat and environmental 
variables, considered to be potentially influential to the likelihood of CAV-1 infection, from freely available digital 
Oligonucleotide 
name Description Nucleotide sequence (5′–3′)b Target(s)a,b
Nucleotide 
position on 
CAV-1 genomeb
CAV-1_hex_F Forward, 1st round CATGGCACACAACACAGC Hexon [partial] 18475–18492
CAV-1_hex_2F Forward, 2nd round GTAAATGACCAGTCCTTTGC Hexon [partial] 18524–18543
CAV-1_hex_R Reverse, 1st round GAATTGTTATGCTGGTGACC Hexon [partial] 19070–19089
CAV-1_hex_2R Reverse 2nd round AAGTGGTAGCCTTGATAGC Hexon [partial] 18942–18960
CAV-1_E3_F Forward, 1st round CTCTGTCTCTCCAATGGC
Putative orf 23/Early E3 22.1 kDA 
glycoprotein Q96688 [partial], 
orf 24, orf 25 [partial] 
25293–25310
CAV-1_E3_2F Forward, 2nd round ACTATCATGCCGCTGAAC
Putative orf 23,/Early E3 
22.1 kDA glycoprotein Q96688 
[partial], orf 24, orf 25 [partial]
25396–25413
CAV-1_E3_R Reverse, 1st round GAGGCGAGATATTCACAGC
Putative orf 23/Early E3 22.1 kDA 
glycoprotein Q96688 [partial], 
orf 24, orf 25 [partial]
26019–26037
CAV-1_E3_2R Reverse, 2nd round GGGGCGTCATATGGATACAC
Putative orf 23/Early E3 22.1 kDA 
glycoprotein Q96688 [partial], 
orf 24, orf 25 [partial]
25929–25948
CAV-1_fib_F Forward, 1st round CCGTGTATCCATATGACGC Fibre [partial] 25927–25945
CAV-1_fib_2F Forward, 2nd round CTCTGGCTGTGAATATCTCG Fibre [partial] 26014–26033
CAV-1_fib_R Reverse, 1st round TTGCTGGAGGTTGAACTGC Fibre [partial] 26490–26508
CAV-1_fib_2R Reverse, 2nd round TAGTACGGTGAGACCCGGAC Fibre [partial] 26455–26474
CAV-1_E4_F Forward, 1st round GCCCACTGTGACTAGAAAGC Putative orf29 Q96692 [partial] and orf30 Q96693 29544–29563
CAV-1_E4_2F Forward, 2nd round CGACACAAATCTGTCTCGC Putative orf29 Q96692 [partial] and orf30 Q96693 29615–29633
CAV-1_E4_R Reverse, 1st round GCTGATTTCCTGAGACGC Putative orf29 Q96692 [partial] and orf30 Q96693 30283–30300
CAV-1_E4_2R Reverse, 2nd round GAGACTTCATTCTCGACAGC Putative orf29 Q96692 [partial] and orf30 Q96693 30207–30226
Table 2.  Summary of additional sequencing primers for CAV-1. aMorrison et al.21. bEMBL: AC_000003.1, 
GenBank Y07760.1.
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environmental data (Table 3). We considered that human population density and land cover may be associated 
with the population density of red foxes and the likelihood of contact between individuals, whereas maximum 
and minimum temperature, relative humidity and precipitation may also be associated with individual immune 
status. Both human density and variables were log10(x + 1) transformed to normalise their distributions.
All explanatory variables were screened for missing values, so that foxes were only included in the model 
if all variables were known, and then evaluated for strong collinearity using bivariable plots for all continuous 
variables. Several of the environmental variables were strongly correlated with each other and with ‘region’. A 
backward stepwise elimination process was used to retain covariates (along with biologically plausible two-way 
interactions) in the multivariable logistic regression model. Variables were retained in the multivariable model 
if they confounded other variables or if they significantly improved model fit at an α -level < 0.05 using the 
likelihood ratio test (LRT). Akaike’s information criterion (AIC) was used to determine which combination of 
variables best explained the data with the minimal number of covariates (i.e. the most parsimonious model). 
The coefficient estimates and standard errors were monitored during model selection for evidence of instability. 
Evidence of overfitting of the model was evaluated using a bootstrapping approach, as suggested by Harrell et al.28, 
and examination of shrinkage of the slope and intercept parameters. An automated step-wise selection based on 
minimising the AIC was also run for comparison.
Goodness-of-fit was ensured by the calculation and plotting of several diagnostic measures (including devi-
ance Δ D, Pearson’s chi-square Δ χ 2 and influence Δ β ) against the predicted probabilities, as suggested by Hosmer 
and Lemeshow (2000)29. The goodness-of-fit of the overall model was further assessed using the area under the 
curve (AUC) of the ROC curve created from the model. Model sensitivity and specificity were estimated at the 
proposed thresholds and their 95% confidence intervals were computed using 2000 bootstrap iterations.
To identify the presence of residual spatial autocorrelation in the data, a binned omni-directional 
semi-variogram30 was constructed over the model’s residuals. Semi-variance was computed over distances of up 
to 10 km and compared to those obtained from a series of 999 Monte Carlo simulations.
Analyses were carried out in R24. The R packages ggplot231 and rgdal32 were used to visualise the distribution 
and IgG status of foxes tested by the CAV ELISA (Fig. 1), using a map of the UK obtained from the Database of 
Global Administrative Areas version 2.833. Other mapping and environmental data extraction procedures were 
carried out using the maptools34 and raster35 packages, respectively. Final model selection was verified by comput-
ing AICc and Δ AIC using the R package AICcmodavg36. Goodness-of-fit procedures were carried out with the 
pROC23 and LogisticDx37 packages, whereas the binned omni-directional semi-variogram was computed using 
the geoR package38.
Results
Prevalence of CAV-1 and CAV-2 by PCR. CAV-1 DNA was detected by nested PCR in tissue DNA 
extracts from 29 of 154 (18.8%, 95% confidence interval, CI 13.2–26.1%) foxes across the UK. One additional fox 
was negative for CAV-1 by PCR in DNA extracts from liver and kidney, but was positive in the spleen, which was 
tested non-routinely prior to confirmation of liver and kidney negativity. Urine and faeces from all foxes, when 
available, were tested for both CAV-1 and CAV-2. Three of 17 (17.6%, 95% CI 4.7–44.2%) urine samples available 
for testing were positive for CAV-1 by PCR. All foxes with positive results in urine were also positive for CAV-1 by 
PCR in liver and kidney. None of 19 foxes were positive for CAV-1 by PCR in faeces and no animals were positive 
for CAV-2 in either faeces or urine.
Distribution and viral load of CAV-1 in fox samples. No animals had gross lesions suggestive of ICH at 
post-mortem examination. However, because of the nature of the samples, tissues from most foxes were not suit-
able for histological processing and examination. Two foxes exhibited mild jaundice at post-mortem examination, 
but both were negative by PCR for CAV-1.
For positive animals, all the available collected samples were screened for the presence of detectable CAV-1 
(PCR results for individual positive animals are summarised in Supplementary Table 1). The tissue distribution of 
CAV-1 and quantification by qPCR, among these positive cases, are summarised in Table 4.
Variable Unit Year
Spatial 
resolution Name and source of data Reference
Human population density km−1 2011 1 km UK gridded population, CEAH Reis et al.52
Relative humidity % 2011 5 km Gridded observation data (UKCP09), Met Office Perry and Hollis
53
Total annual rainfall mm 2011 5 km Gridded observation data (UKCP09), Met Office Perry and Hollis
53
Mean monthly maximum temperature °C 2011 5 km Gridded observation data (UKCP09), Met Office Perry and Hollis
53
Mean monthly minimum temperature °C 2011 5 km Gridded observation data (UKCP09), Met Office Perry and Hollis
53
Altitude m — 1 km
The Shuttle Radar Topographic 
Mission (SRTM) digital elevation 
data, CGIAR-CSI
Jarvis et al.54
Land cover class — 2012 250 m
Corine Land Cover European 
database, Copernicus Land 
Monitoring Services
European Environment 
Agency55
Table 3.  Additional explanatory variables used in the regression model development with data source.
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Prevalence of IgG antibodies against CAV-1. Across the UK, the sera of 302 of 469 (64.4%, 95% CI 
59.8–68.7%) red foxes were estimated to be positive for IgG antibodies reactive against CAV-1 by ELISA. Amongst 
CAV-1 PCR positive foxes subjected to serological testing, 20 of 25 (80%, 95% CI 58.7–92.4%) foxes with blood 
available for serology had IgG reactive against CAV-1 by ELISA. Amongst CAV-1 PCR negative foxes, 48 of 103 
(46.6%, 95% CI 36.8–56.7%) were positive for IgG reactive against CAV-1. IgG antibodies reactive against CAV-2 
by ELISA were detected in 264 of 469 (56.3%, 95% CI 51.7–60.8%) foxes. The cross-reactivity between CAV-1 and 
CAV-2 was high (84.1%, 95% CI 79.4–87.8%). Of foxes positive for CAV IgG, 254 of 312 (81.4%) were estimated 
to have IgG reactive to both CAV-1 and CAV-2, whereas 48 of 312 (15.4%) animals had IgG reactive to only to 
CAV-1. Only 10 of 312 (3.2%) animals had antibodies which were reactive only to CAV-2.
Amongst the subset of red foxes with associated spatial data, included in the multivariate model, 257 of 387 
(66.4%, 95% CI 61.4–71.1%) foxes were seropositive for CAV. Initial plotting of the spatial distribution suggested 
a possible north/south trend in prevalence, with a higher prevalence in the south of the UK (Fig. 1). Looking at 
the regional differences, 37 of 72 (51.4%, 95% CI 39.4–63.2%) in NI were CAV seropositive, compared to 220 of 
315 (69.8%, 95% CI 64.4–74.8%) in GB; this difference was statistically significant (χ 2 = 8.14, df = 1, p = 0.004). 
This initial difference was largely explained by a significant difference in the age structure of the foxes in the sam-
ples from NI and GB (χ 2 = 19.89, df = 2, p < 0.001).
In total, 11 variables were tested for association with the odds of foxes being CAV seropositive, including 
region, age, sex, BCS and the seven environment and habitat variables (Table 3). The final model included the 
age and sex of the sampled foxes, as well as the mean monthly maximum temperature recorded at the capture/
collection site. Compared to being a juvenile fox, being an aged adult fox significantly increased the odds of being 
CAV seropositive by a factor of 2.75 (95% CI 1.11–6.93), whereas young adult foxes were not significantly more 
likely to be CAV seropositive (odds ratio, OR, 1.51, 95% CI 0.67–3.46).
Figure 1. Spatial distribution of red foxes sampled in the United Kingdom (n = 387), according to canine 
adenovirus (CAV) IgG status. Jittering of data points was applied to improve the differentiation of overlapping 
data points. The map was created in R24,33.
www.nature.com/scientificreports/
8Scientific RepoRts | 6:36051 | DOI: 10.1038/srep36051
There was no statistically significant difference between male and female foxes in the likelihood of being CAV 
seropositive (OR for male compared to female foxes 0.70, 95% CI 0.45–1.10), but this variable was retained in 
the model to adjust for potential confounding. The mean monthly maximum temperature was the most influen-
tial variable in the model, accounting for 60% of the deviance explained. For each degree increase in the mean 
monthly maximum temperature, the odds of being CAV seropositive increased by a factor of 1.45 (CI 1.23–1.71). 
Adding the variable ‘region’ with or without the temperature variable did not improve the fit of the model, con-
firming that the effect of temperature was not related to the spatial location of the foxes.
The AUC of the final model was 0.68 (95% CI 0.62–0.73) and the index corrected shrinkages for the intercept 
and slope were 0.047 and 0.922, respectively. There were no overly influential covariate patterns observed in 
subsequent model diagnostic plots and there was no residual spatial clustering detected when semi-variance was 
evaluated. This suggests that the model has reasonable explanatory power and little of evidence of overfitting.
CAV-1 sequence analysis. Sequences obtained using the additional sequence primers (Table 2) were sub-
mitted to GenBank under accession numbers KU755693 to KU755761. Sequences obtained using the detection 
primer set were not submitted due to their relatively short length (< 200 bp). The sequences obtained using all 
primer sets shared 99–100% identity with the reference genome (EMBL AC_000003.1). However, all sequences 
obtained from the hexon region, using the CAV-1_hex primer set (n = 17), were identical to the reference genome 
in all foxes (GenBank accession numbers KU755693 to KU755701).
Single nucleotide changes which were unique to foxes from GB or NI were identified in other amplified 
genomic regions, in addition to several single nucleotide changes, which were present mostly, but not solely, 
in one of the populations; these are summarised in Fig. 2. These changes may represent single nucleotide poly-
morphisms (SNPs). Single nucleotide changes in relation to the CAV-1 reference genome, which were present in 
two or less foxes from which sequences were obtained, were also identified (Fig. 2); these were verified by repeat 
sequencing in both forward and reverse directions to negate sequencing errors.
Discussion
This study has shown that 18.8% of red foxes from across the UK, all of which were free from gross evidence 
of ICH on post-mortem examination, were positive for CAV-1 sequences by PCR, consistent with inapparent 
infection. A range of tissues were infected and 50% of urine samples from CAV-1 infected foxes were also positive 
for CAV-1 by PCR. The majority of foxes with detectable CAV-1 DNA also had antibodies against CAV, which 
strongly suggests that CAV-1 may establish persistent infections in foxes. The majority (64.4%) of red foxes from 
across the UK had antibodies against CAV, indicating that the red fox is likely to be a significant wildlife reservoir 
for CAV-1 in the UK.
It is not possible to estimate how many CAV-1 infections in free-ranging foxes actually result in clinical ICH 
and how many foxes will die from the disease, despite mortality being reported to be up to 25% in experimental 
infections in captive foxes5. Most cases of ICH are likely to go unnoticed (or undiagnosed) in free-ranging ani-
mals and many affected foxes are likely to die underground in their dens, so that the carcasses are never found 
and examined. In the present study, all of the CAV-1 infections were inapparent, suggesting that a proportion 
of red foxes do not develop fatal ICH, but instead become persistently infected. Given the high number of red 
foxes which were estimated by ELISA and PCR to have been exposed to CAV-1, it appears that many animals are 
subclinically infected or develop only mild ICH, from which they recover. It is possible that some foxes are pro-
tected from CAV-1 by maternal antibodies when young and subsequently develop acquired immunity through 
intermittent exposure to CAV-1 from infected conspecifics.
Aged adult foxes were significantly more likely to have antibodies against CAV than juvenile foxes, consistent 
with a longer period of potential exposure to CAV-1. Given that protective antibody titres towards CAV appear to 
be maintained in most dogs which have not been vaccinated for more than 3 years39, and that the mean lifespan 
of free-ranging, urban red foxes in the UK was as low as 2.1 years for subordinate individuals in one study40, it 
is likely that infection and exposure to CAV-1 promotes lifelong persistence of antibodies against CAV in most 
foxes. CAV-1 appears to be highly prevalent in the UK. Therefore, initial infection may occur early in life follow-
ing the waning of any maternal immunity and these surviving juvenile animals then progress to adulthood. In 
the present study, 20% of foxes were positive for CAV-1 by PCR, but did not possess detectable antibodies against 
CAV. These may have been only recently exposed to CAV-1, and thus may not yet have developed IgG, or this 
could be a consequence of the high ELISA cut-off value in this study. It is notable that 80% of foxes which were 
PCR positive for CAV-1 possessed detectable antibodies against CAV; this suggests that CAV-1 possesses effective 
mechanisms to evade the immune system and persist in the foxes. However, it should be noted that cell-mediated 
immunity was not measured in this study.
Liver Kidney Blood Spleen Brain Lung GIT Urine Faeces
Percentage (%) of CAV-
1 PCR positive foxes 85 (n = 29)
61.9 
(n = 29)
27.3 
(n = 22) 83.3 (n = 6)
62.5 
(n = 8) 33.3 (n = 9)
0 
(n = 4) 50 (n = 6)
0 
(n = 6)
Mean CAV-1 genome 
copies/μ L 1.15 × 10
3 6.50 × 103 1.14 × 101 5.45 × 102 BLD 1.43 × 101 — 1.42 × 104 —
Standard deviation 2.66 × 103 2.30 × 104 2.27 × 101 1.06 × 103 — 1.69 × 101 — 2.41 × 104 —
Table 4.  Distribution of CAV-1 infection among tissues/samples in foxes positive for CAV-1 by PCR, and 
estimation of viral load (genome copies per μL) by qPCR.  GIT, gastrointestinal tract; BLD, below the limits of 
detection.
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The seropositivity in this study (64.4%) is higher than has been previously estimated in the UK7. This find-
ing is likely to be a result of the large sample size, a more sensitive serological diagnostic test and the use of 
blood instead of tissue fluids, rather than a temporal increase in seroprevalence since the time of the survey by 
Thompson et al.7. The relatively high CAV seroprevalence in the present study should not be viewed as an unusual 
finding, since it is consistent with a seroprevalence of 59.7% reported in red foxes in Norway41; furthermore, con-
siderably higher estimates of seroprevalence of CAV have been estimated in other canid species11,42.
Geographical differences in CAV seroprevalence were observed, with red foxes from southern regions of GB 
being more likely to be seropositive than those from the north; this association was related to mean monthly max-
imum temperature. Such an association is most likely to be related to an unobserved variable, such as fox density; 
fox populations and thus densities are estimated to be higher in the south of GB14. Together with the effect of 
temperature and longitude (possibly related to an unobserved variable, such as population density), the difference 
in the age structure of the sampled fox populations between NI and GB may account for the observed lower sero-
prevalence of CAV in red foxes in NI. The study population was largely obtained through convenience sampling 
and, although it represents a relatively large sample of foxes from across the UK, inferences from the analyses may 
be biased. However, it is unlikely that biases through convenience sampling are associated with CAV infection, 
so can be controlled for in the modelling process. Alternatively, it is possible that the population structure and 
dynamics of red foxes in Ireland (NI and the Republic of Ireland) are different to those in GB. However, detailed 
studies on the structure of the Irish red fox population have not been published to date.
The high serological cross-reactivity between CAV-1 and CAV-2 is somewhat, but not wholly, addressed using 
inferences from the associated molecular survey and from clinical evidence. We found that numerous foxes in the 
UK had evidence of infection with CAV-1 by PCR. However, CAV-2 was not detected in the urine or faeces of any 
red foxes tested. In addition, although there is a single report of a CAV-2 sequence being detected by PCR in the 
faeces of a red fox13, there is no definitive evidence to suggest that CAV-2 is a frequent infection or causes disease 
in this species. Therefore, red foxes are unlikely to be a major transmitter of CAV-2 in the UK.
Although persistent excretion of virus in urine has been observed in dogs which have recovered from clinical 
disease after experimental infection with CAV-116, it has not been demonstrated previously that free-ranging 
foxes with molecular evidence of inapparent infection with CAV-1 in tissues also shed CAV-1 in urine. Despite the 
low sample size, it should be noted that the viral load of CAV-1 was relatively high in urine (Table 4), suggesting 
Figure 2. Summary of the common, single nucleotide changes among sequences obtained from foxes 
in Great Britain (England and Scotland) and Northern Ireland, and the associated GenBank accession 
numbers. 
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that this may be an important sample to screen in epidemiological studies of CAV-1 and possibly as a monitoring 
tool in wildlife hospitals which regularly admit red foxes. Adenoviruses are considered to be moderately resistant 
in the environment1. Therefore, a susceptible red fox, dog or other susceptible species which comes into contact 
with the recently voided urine of a CAV-1 shedding fox is likely to be at risk of infection.
Although Balboni et al.13 found that 2 of 32 (6.3%) red foxes in Italy excreted CAV-1 in faeces, there was no 
evidence of excretion of CAV-1 in faeces from red foxes in our study. Faeces generally are not considered to be a 
primary route of excretion of CAV-1 in animals which have recovered from ICH1. However, it is possible that the 
detection of CAV-1 may have been limited as a consequence of the small number of samples screened. Although 
faeces can contain PCR inhibitors, adenoviruses have been successfully detected in faecal samples in other stud-
ies13,43,44 and the faecal DNA extraction kit selected was chosen to improve the removal of PCR inhibitors.
In addition to liver and kidney, the spleen, lung and brain were shown to be infected with CAV-1 in some red 
foxes in the present study. Therefore, CAV-1 appears to establish possibly persistent infections in a range of tissues 
corresponding to those most often affected during the clinical course of severe ICH4. There would be value in 
testing gastrointestinal and oral lymphoid tissues for evidence of CAV-1, particularly since oral lymphoid tissues, 
have been shown to be sites of adenovirus persistence in humans, associated with intermittent excretion in faeces 
in humans and non-human primates43,44.
Some differences in viral load were found between sample types by qPCR; for example, relatively high loads 
were observed in urine, kidney and liver compared to the brain, in which viral loads were too low to be quantified. 
However, due to the small number of samples tested from these sites, it was not possible to apply statistical anal-
ysis to the data. In view of the low viral loads in some tissues, a highly sensitive molecular assay, such as nested 
PCR, is necessary to estimate the true prevalence of inapparent infections with CAV-1.
Since the present study has provided evidence for inapparent infections in red foxes, further molecular exper-
imental studies are required to investigate the pathogenesis of persistent CAV-1 infections and the viral or host 
mechanisms which underlie this. Some similarities are evident between inapparent CAV-1 infections in red foxes 
and human adenoviruses43,45,46. However, it is notable that, in this study, CAV-1 DNA was detected in a range of 
functionally distinct lymphoid and non-lymphoid tissues, in otherwise healthy animals. Moreover, in humans, 
it is unclear whether, in some cases, systemic disease is a result of recrudescence of a persistent infection or as a 
result of infection in transplanted tissues (e.g. in transplant recipients)47,48. Whether similar recrudescence events 
can occur in persistently infected non-human species is not known, but would be of particular importance when, 
for example, a free-ranging animal is brought into captivity (i.e. hospitalised), which may result in considerable 
individual stress. Some CAV-1 proteins in the early expressed (E) regions have low similarity to E gene products 
of human adenoviruses21, so CAV-1 may possess unique evasion mechanisms.
It was not possible to determine the duration of CAV-1 persistence in red foxes, or the cell type(s) that support 
persistence. Suitable in vitro models using canine or vulpine cell lines could be used to investigate the pathogen-
esis of CAV-1 persistence. It is unclear whether CAV-1 detected by PCR in the organs of carrier foxes is viable 
and capable of lytic infections in permissible cell lines; this could be investigated using freshly harvested tissues.
This study also presents evidence of genetic variation in the sequences of CAV-1 in foxes from different regions 
in the UK. This manifests as single nucleotides changes (or possible SNPs) in different regions of the CAV-1 
genome, with some nucleotide variants appearing to be unique to foxes from GB or NI. Genetic variation may be 
a result of genetic drift caused by the disruption of gene flow between GB and Ireland, which are geographically 
separated by the Irish Sea. Such spatial variation in the CAV-1 genome has not been reported previously. There 
may be a variable rate of divergence in different regions of the CAV-1 genome, since sequences obtained from the 
hexon region were invariant, whereas others were more variable. The sequences from the possible multiple CAV-1 
field strains circulating in red foxes in the UK are different to those which historically have been detected in dogs 
in the UK and Europe. The reference genome for CAV-1 was sequenced from a field strain isolated from a dog in 
the UK in 199621. Two CAV-1 sequences reported in dogs from Italy from 2012 were identical to this reference 
sequence, although only the CAV-1 E3 region was sequenced in these cases49. CAV-1 molecular epidemiologi-
cal studies should be extended to dogs and red foxes in other countries, and other genomic regions should be 
sequenced to allow direct comparisons with the CAV-1 sequences obtained in the present study.
Conclusion
ICH is now generally considered to be a relatively uncommon disease in domestic dogs in areas where vaccina-
tion is performed routinely. However, because a high proportion of red foxes in the UK are inapparently infected 
with CAV-1 and, in some cases, CAV-1 is shed in the urine, it is recommended that all dogs continue to be 
routinely vaccinated against ICH (using CAV-2-based vaccines). Consideration of current wildlife reservoirs of 
disease should also be strongly considered in the planned or potential reintroductions of susceptible free-ranging 
carnivores to historical habitats, for example the debated reintroduction of wolves into Scotland50,51, which may 
become an additional reservoir of CAV-1 in the UK. Consideration should also be given to the management and 
vaccination of red foxes in wildlife rescue centres to prevent outbreaks of ICH4. Small animal veterinarians should 
be aware that there is a risk of infection in unvaccinated animals, and ICH should be suitably considered in the 
differential diagnoses of critically unwell, unvaccinated dogs and other susceptible species with supporting clini-
cal history. It is likely to be both practically and financially unfeasible to attempt a disease eradication programme 
for CAV-1 in red foxes in the UK.
As the only free-ranging canid species in the UK, the red fox is deemed to be the primary wildlife reservoir of 
CAV-1. Other canid species may be the primary, or an additional reservoir, of the virus in other countries, and 
sensitive molecular methods should be employed to investigate this. Further molecular studies investigating the 
pathogenesis of CAV-1 should specifically aim to identify the viral mechanism(s) which may permit CAV-1 to 
persist in the tissues of infected hosts.
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